Considering Proximal Urea Cycle Disorders in Expanded Newborn Screening
1
Public Health Genetics, University of Washington, Seattle, WA 98195, USA
2
Newborn Screening Laboratory, Public Health Laboratories, Washington State Department of Health, Shoreline, WA 98155, USA
3
Department of Pediatrics, University of Washington, Seattle, WA 98105, USA
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(4), 77; https://doi.org/10.3390/ijns6040077
Received: 15 August 2020
/
Revised: 20 September 2020
/
Accepted: 29 September 2020
/
Published: 8 October 2020
Proximal urea cycle disorders (PUCDs) have adverse outcomes such as intellectual disability and death, which may benefit from newborn screening (NBS) through early detection and prevention with early treatment. Ornithine transcarbamylase deficiency (OTCD) and carbamoyl phosphate synthetase 1 deficiency (CPS1D) are screened in six and eight states in the United States. We analyzed current evidence to see if it supports inclusion of PUCDs in the NBS panels based upon prevention potential, medical, diagnostic, treatment, and public health rationales. A literature review was performed in PubMed using MESH terms for OTCD, CPS1D, and NAGSD. A systematic review was performed in the hallmark of NBS inclusion criteria. We reviewed 31 articles. Molecular and biochemical diagnosis is available to provide diagnostic evidence. Untreated PUCDs have a significant burden with considerable developmental delay and mortality that may improve with early treatment. Tandem mass spectrometry can be used for NBS for PUCDs; however, citrulline and glutamine alone are not specific. Medical treatments currently available for PUCDs meet existing medical, diagnostic, treatment, and public health rationales. Improvement in NBS algorithms to increase sensitivity and specificity will allow earlier diagnosis and treatment to potentially improve disability and mortality rates.
View Full-Text
Keywords:
proximal urea cycle disorders; ornithine transcarbamylase deficiency; carbamoyl phosphate synthetase 1 deficiency; N-acetyl glutamate synthetase deficiency; neonatal screening; public health; newborn screening; NBS
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 735 KiB)
MDPI and ACS Style
Vasquez-Loarte, T.; Thompson, J.D.; Merritt, J.L., II. Considering Proximal Urea Cycle Disorders in Expanded Newborn Screening. Int. J. Neonatal Screen. 2020, 6, 77. https://doi.org/10.3390/ijns6040077
AMA Style
Vasquez-Loarte T, Thompson JD, Merritt JL II. Considering Proximal Urea Cycle Disorders in Expanded Newborn Screening. International Journal of Neonatal Screening. 2020; 6(4):77. https://doi.org/10.3390/ijns6040077
Chicago/Turabian StyleVasquez-Loarte, Tania, John D. Thompson, and J. L. Merritt II. 2020. "Considering Proximal Urea Cycle Disorders in Expanded Newborn Screening" International Journal of Neonatal Screening 6, no. 4: 77. https://doi.org/10.3390/ijns6040077
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
